# Rigosertib for RDEB-SCC

> **NCT03786237** · PHASE1,PHASE2 · COMPLETED · sponsor: **Prof. Johann Bauer** · enrollment: 2 (actual)

## Conditions studied

- Epidermolysis Bullosa Dystrophica
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Rigosertib Oral Capsules / Rigosertib Intravenous

## Key facts

- **NCT ID:** NCT03786237
- **Lead sponsor:** Prof. Johann Bauer
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786237, "Rigosertib for RDEB-SCC". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03786237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*